Alexandra Stolzing, PhD


Loughborough University

Centre for Biological Engineering

Loughborough, UK
Senior Lecturer in Regenerative Medicine
→ Group Webpage
+44 (0) 150 9227577
Alexandra Stolzing_CV.doc

CV google


The study of cellular aging and the development of regenerative therapies.   


◊◊ Cellular Reprogramming

My group is investigating ways to utilise cellular reprogramming technologies in order to re-instate regenerative capacity in aged tissue and in niches of aged stem cells. We study 4 main approaches:

Cellular Fusion: Cell fusion occurs spontaneously in humans after bone marrow transplantation or stem cell injections and is also part of the natural maintenance of several tissues. Silenced genes can become activated upon fusion and cells become infused with 'young' factors. An understanding of the intracellular regulatory network will enhance our ability to enlist this potential to direct changes and lead cells towards a specialized differentiation state or roll back the genetic age of a cell.

Induced Pluripotency: This group is applying a novel technique to de-differentiate aged and specialised cells towards a pluripotent state which has a similar differentiation potential to embryonic stem cells. The group uses mRNA to reprogramme cells safely without genomic alterations.

Cell Conditioning: Insights from basic ageing studies have helped us to develop advanced protocols for modulating cell fate and cell survival. By applying specially adapted cell culture techniques, a carefully monitored environment and by supplementation with certain cell culture factors, we are refining methods of maintaining and increasing the differentiation potential of adult stem cells.

◊◊ Aging interventions

Aging Stem Cells: The capacity of adult stem cell to assist with the regeneration of tissue and organs seems to decline during aging. 
I am investigating which factors determine how progenitor cells change during aging. From this understanding, we can develop techniques to alter the differentiation behavior of aged progenitor cells.
Such technologies will be particularly critical for the use of stem cell therapies in the elderly or in people with diseases, in which the autologus stem cell quality might be impaired. 
My group attempts to ‘prime’ stem cells via a novel combination of methods with the aim of increasing their capacity to regenerate in vivo.

Microglia Replacement Therapy: During aging, the role of microglia in the brain changes from ‘friend to foe’ –in young organisms microglia are actively participating in clearing protein debris from the brain and are renewed by adult stem cells. In aged and old organisms however, microglial replenishment is impaired. The brain is burdened with ‘old’ microglia that remain in chronic activation and thus cause inflammation and damage. 

Our goal is to slow brain aging by supporting exciting cells and by reactivating endogenous stem cells. If you want to support us and help with our research please donate.

◊◊ Cryopreservation of cells

Cryopreservation is a process where whole tissues or cells are preserved by cooling to sub-zero temperatures. Such low temperatures assure that any biological activity is effectively stopped, including reactions that could lead to the deterioration of cells. Vitrification is a specialized form of cryopreservation converting a material into a glass-like form that is free from crystalline structures.

Cryopreservation exposes cells to significant stresses. Factors like fluctuation in temperature during freezing & thawing, and the use of inadequate cryoprotectant combinations can damage cells and tissues.

We aim to eliminate traditional cryoprotectants like DMSO in stem cell culture and to refine a cryopreservation method that improves the viability and differentiation potential of stem cells and stem-cell derived tissues.


I am always interested in collaborating with colleagues in academia and the private sector alike.
Applications from research students with an interest in gerontology or cell therapy are also welcome.